Klebsiella Aerogenes: Traits, Transmission, and Resistance

Klebsiella aerogenes is a Gram-negative bacterium that lives in the human gut and the wider environment, and it has earned growing attention in hospitals because of its talent for resisting antibiotics. Until recently it went by a different name, Enterobacter aerogenes, before genomic analysis moved it into the Klebsiella genus.¹ That reclassification is more than a bookkeeping detail: it reflects genetic kinship with Klebsiella pneumoniae and has practical consequences for how clinicians interpret lab results and choose drugs.

A Bacterium Between Two Genera

For decades, clinical microbiology labs filed this organism under Enterobacter, grouping it with organisms like Enterobacter cloacae. Whole-genome comparisons eventually showed it clusters more closely with Klebsiella species, and in 2017 the taxonomic reclassification was formally proposed. The name change has caused real confusion in hospitals. Older literature, antibiograms, and even automated identification systems still reference “Enterobacter aerogenes,” so clinicians sometimes have to reconcile results from two naming eras for what is the same organism.

Genomic surveys have catalogued hundreds of isolates worldwide. One large analysis examined 561 genomes spanning samples collected from 1955 to 2022 across 37 countries. The vast majority came from human infections, though a small fraction were traced to animals or the environment. The dataset was heavily weighted toward the United States, which contributed about 44% of all sequenced genomes, and two sequence types, ST93 and ST4, dominated globally.² That sampling bias matters: we know far more about K. aerogenes strains circulating in North American and European hospitals than those elsewhere, and the true global diversity is almost certainly underrepresented.

What Makes It Dangerous

K. aerogenes is not the most virulent member of its genus, but it carries a suite of tools that help it survive inside a host and evade immune defenses. Genomic analyses have identified two distinct population clusters defined by different virulence profiles. One cluster carries the colibactin-encoding clb operon, a set of genes linked to DNA-damaging toxin production, along with siderophore genes (irp and ybt) that scavenge iron from host tissues.³ Iron acquisition is critical for bacterial growth during an infection because the human body actively withholds iron as part of its innate defense, so bacteria that carry their own iron-grabbing machinery have a survival advantage.

Another distinguishing feature is a specialized secretion system. K. aerogenes isolates belonging to the KAC lineage carry a type i3 T6SS gene cluster, a molecular syringe the bacterium uses to inject toxic proteins into competing microbes and, potentially, host cells. This version of the secretion system is different from the type i2 T6SS found in other Klebsiella species, and researchers suspect it was picked up through horizontal gene transfer rather than inherited vertically.⁴ That kind of lateral acquisition is a recurring theme with this organism: it readily borrows genetic material from its neighbors.

Biofilm formation adds another layer of concern. K. aerogenes can colonize medical devices and form dense biofilm communities that shield individual cells from both antibiotics and immune cells. This trait is directly relevant in ventilator-associated pneumonia, one of the more common serious infections the bacterium causes.⁵

How It Spreads in Hospitals

K. aerogenes lives harmlessly in the gastrointestinal tract of many healthy people, so the organism is never far from hospital patients. Problems start when it reaches a site it should not be, usually through contaminated hands, medical equipment, or fluids. Hospital outbreaks have been traced to an almost comically wide range of sources: total parenteral nutrition solutions, saline bags, albumin preparations, digital thermometers, intravenous catheters, mechanical ventilators, and dialysis equipment.⁶ The common thread is moist or fluid-filled environments where the bacterium can persist and multiply.

Transmission does not always involve high-tech medical devices. One outbreak in a neurosurgical department was eventually linked to contaminated shampoo equipment operated by an outsourced barber service, a finding that underscored how non-clinical services within a hospital can become blind spots for infection control.⁷ When infection control teams focus exclusively on ICU surfaces and ventilator circuits, reservoirs in ancillary services can quietly sustain transmission.

Investigations of hospital clusters have sometimes revealed a surprise: despite apparent outbreaks, whole-genome sequencing showed that the isolates were genetically unrelated, meaning multiple patients acquired the same species independently rather than passing it to one another.⁸ This highlights that K. aerogenes is common enough in patient gut flora that a cluster of cases can arise from endogenous colonization rather than a single contaminated source. Distinguishing true person-to-person transmission from coincidental endogenous infections requires genomic-level investigation, which is still not routine in many hospitals.

The Resistance Problem, Starting With the Built-In Defenses

K. aerogenes is intrinsically harder to treat than many other gut bacteria because it comes pre-loaded with a chromosomal AmpC enzyme. Under normal conditions, this enzyme is produced at low levels and does not cause much trouble. But exposure to certain antibiotics, particularly older cephalosporins and some penicillins, can induce the bacterium to ramp up AmpC production dramatically. The result is that a drug that appeared to work in the lab can fail at the bedside as the organism cranks out enough enzyme to destroy it. This inducible AmpC expression is the single most clinically important intrinsic resistance trait the species carries.

K. aerogenes pairs that enzymatic defense with a permeability barrier in its outer membrane. Its porins, the channels that let molecules cross the outer membrane, can mutate to become narrower or disappear entirely. Researchers studying imipenem resistance found that strains carrying a specific mutation in the OmpK36 porin had their pore diameter reduced by roughly 15%, which on its own was not enough to cause resistance. When a second mutation knocked out the porin entirely, though, the combination of a blocked entry point plus AmpC-mediated drug destruction pushed the bacterium past the resistance threshold.⁹ This synergy between a “permeability barrier” and “enzymatic hydrolysis” is a recurring pattern and makes the organism particularly hard to corner with a single drug class.

On top of enzyme production and porin changes, active efflux pumps round out the defense. These molecular pumps sit in the cell envelope and actively eject antibiotics that manage to get inside, including quinolones and chloramphenicol. Clinical strains have been found deploying all three mechanisms simultaneously: reduced porin permeability, AmpC expression, and efflux.¹⁰ When a single bacterial cell runs all three systems at once, even drugs that should theoretically work against it lose their punch.

Acquired Resistance Through Plasmids and Mobile Elements

The intrinsic toolkit is concerning enough, but K. aerogenes also acquires new resistance genes from the broader bacterial community via plasmids, small circles of DNA that bacteria swap through direct contact. A global genomic survey found over a hundred plasmids carrying resistance genes across sequenced K. aerogenes genomes, with individual plasmids harboring anywhere from one to twelve resistance genes targeting cephalosporins, carbapenems, aminoglycosides, sulfonamides, macrolides, and quinolones.² Many of these plasmids were classified as conjugative, meaning they carry the machinery to transfer themselves into new bacterial hosts without any outside help.

Carbapenem resistance genes are the most worrying plasmid cargo, because carbapenems are often drugs of last resort for serious Gram-negative infections. In a set of carbapenem-resistant K. aerogenes isolates from a teaching hospital in southwestern China, researchers found multi-drug resistance genes throughout the collection: roughly two-thirds carried ampC genes, over a third carried extended-spectrum beta-lactamase genes, and a smaller number carried bla NDM-1 or bla KPC-2, the enzymes most associated with untreatable infections.¹¹ The KPC-2 and NDM genes are frequently carried on conjugative plasmids belonging to specific families (IncFIIK and IncX3, respectively) and are shuttled between bacteria by transposons, short mobile genetic elements that hop between plasmids and chromosomes.¹²

Resistance can also emerge during treatment itself. One documented case showed a patient’s K. aerogenes isolate developing resistance to ceftazidime/avibactam, a newer combination antibiotic, while the patient was actively receiving the drug. Genome sequencing of isolates collected before and during treatment revealed a single mutation in the AmpC enzyme that altered how the drug docked to its target.¹³ This is particularly unsettling because ceftazidime/avibactam was specifically designed to overcome AmpC resistance. When the bacterium can outmaneuver even the drugs built to defeat its defenses, the arms race between drug development and bacterial evolution becomes uncomfortably visible.

When Even Last-Resort Drugs Fail

Colistin (polymyxin) has been revived as a last-line treatment for multidrug-resistant Gram-negative infections, including those caused by K. aerogenes. But resistance to colistin has already been documented. In Bulgaria, a critically ill patient with septic shock yielded a K. aerogenes isolate with high-level colistin resistance. Investigators found no mobile colistin resistance (mcr) genes, the transferable resistance mechanism that most alarms public health officials. Instead, the resistance arose from mutations in the PmrA/PmrB regulatory system, which controls how the bacterium modifies its outer membrane to repel polymyxins.¹⁴

A separate case in Brazil identified a K. aerogenes isolate resistant to both carbapenems and polymyxin B. That strain carried KPC-2 for carbapenem resistance plus alterations in the phoP gene as a suspected mechanism for polymyxin resistance, and it also harbored an array of additional beta-lactamase and ESBL genes.¹⁵ Strains resistant to every available conventional antibiotic are still rare, but the fact that they exist at all is a clear signal that new therapeutic strategies are needed.

Treatment Options and Their Limits

For susceptible K. aerogenes infections, carbapenems remain highly effective. Surveillance data from Spain covering 2016 to 2022 found that carbapenems maintained activity above 90% against K. aerogenes, and newer combination agents such as ceftazidime/avibactam, imipenem/relebactam, and meropenem/vaborbactam topped 95% activity.¹⁶ Ceftolozane/tazobactam performed less well, with activity around 80% against both K. aerogenes and the related E. cloacae complex.

Piperacillin/tazobactam is a notably poor choice. A multicenter study examining AmpC-hyperproducing isolates found resistance rates to piperacillin/tazobactam as high as about 82%, and even cefepime, which is generally regarded as more stable against AmpC, showed resistance up to roughly 20%.¹⁷ The practical takeaway is that conventional beta-lactam/inhibitor combinations are unreliable once AmpC is derepressed, and clinicians need to consider newer agents or carbapenems for serious infections.

For infections caused by carbapenem-resistant strains, the drug menu shrinks dramatically. Ceftazidime/avibactam and meropenem/vaborbactam remain active against many such isolates, but as noted, resistance to these newer drugs can develop on therapy. When resistance extends to carbapenems and polymyxins alike, clinicians face agonizing choices involving combination regimens with uncertain evidence and limited clinical data.

Clinical Outcomes in Bloodstream Infections

Despite its fearsome resistance repertoire, K. aerogenes bloodstream infections have not consistently shown worse outcomes than those caused by related species. A multicenter cohort study comparing K. aerogenes, K. pneumoniae, and E. cloacae bacteremia found that mortality or recurrence was less frequent in K. aerogenes cases (about 7%) compared to E. cloacae (about 21%) or K. pneumoniae (about 19%), though the differences did not reach statistical significance.¹⁸ K. aerogenes infections did tend to cause more prolonged fever and were more frequently associated with device-related infections, consistent with the organism’s biofilm-forming tendencies.

An earlier study specifically examining K. aerogenes bloodstream infections against other Enterobacter species found that K. aerogenes was associated with poorer clinical outcomes relative to other Enterobacter.¹ These apparently contradictory findings reflect a real pattern in the literature: outcomes depend heavily on what you compare against. K. aerogenes looks relatively benign next to K. pneumoniae but may fare worse next to other Enterobacter species. Patient populations, resistance profiles, and the specific clinical settings also vary across studies, making clean comparisons difficult.

The Organism Outside the Hospital

K. aerogenes is not confined to healthcare settings. It circulates in the wider environment, and the resistance genes it picks up in hospitals do not stay there. Investigations of riverine environments receiving hospital wastewater have isolated multidrug-resistant K. aerogenes alongside other resistant organisms, confirming that hospital effluent serves as a conduit for resistance genes into waterways.¹⁹ From there, resistant bacteria can colonize people, animals, and soils, completing a loop that public health researchers call the “One Health” cycle. The global genomic survey mentioned earlier found isolates from animals and environmental sources carrying the same resistance gene families found in human clinical strains, suggesting the exchange is already well established.

Efflux pumps and porin modifications provide a survival advantage not just against antibiotics but also against environmental stresses like bile salts and detergents. This versatility helps explain why K. aerogenes persists so well in the gut, on hospital surfaces, in wastewater, and on medical equipment. Its adaptability is not driven solely by antibiotic pressure; it is a generalist that thrives in fluctuating environments, and antibiotic resistance genes happen to be part of the toolkit it has assembled along the way.

Phage Therapy and Future Approaches

With conventional antibiotics losing ground, researchers are revisiting bacteriophages, viruses that specifically infect and kill bacteria, as an alternative or complement to drug therapy. A phage called pK4-26, isolated from hospital sewage, showed strong lytic activity against multidrug-resistant K. aerogenes in laboratory and animal studies. In a pneumonia model, the phage reduced bacterial loads, lowered mortality, and alleviated lung inflammation without obvious side effects. It also carried a depolymerase enzyme capable of stripping the bacterial capsule and dismantling biofilms, which effectively re-exposed the bacteria to the host immune system.⁵

Delivering phages to the gut presents its own challenges, since stomach acid rapidly inactivates free phage particles. One research group developed a chitosan-sodium alginate bead system supplemented with honey, casein, and gelatin that protected a phage cocktail at stomach-like pH levels as low as 1.5. When the beads reached simulated intestinal conditions, the phages were released over about five hours and reduced K. aerogenes counts by over six orders of magnitude, far more than unprotected phages achieved.²⁰ These are early-stage studies, and phage therapy faces regulatory and manufacturing hurdles that keep it far from routine clinical use. But for an organism that has already figured out how to dodge carbapenems and polymyxins, the prospect of therapies that attack it through an entirely different mechanism is appealing.

Why Infection Control Keeps Struggling

Standard infection prevention measures, including hand hygiene, contact precautions, and environmental cleaning, remain the front line against K. aerogenes transmission. But hospital outbreaks involving carbapenem-resistant strains have continued even after aggressive implementation of these interventions.²¹ Part of the difficulty is that K. aerogenes colonizes the gut silently. A patient can carry a resistant strain without any symptoms, shedding it into the hospital environment and seeding the organism onto surfaces and shared equipment long before anyone suspects a problem.

The genomic finding that apparent clusters sometimes turn out to be unrelated strains complicates matters further. When infection control teams see a rise in K. aerogenes cases and assume person-to-person spread, they focus on breaking chains of transmission. If the strains are actually arising independently from patients’ own gut flora, the interventions targeting transmission will not solve the problem. The answer in those situations lies more in antimicrobial stewardship, reducing the drug pressure that selects for resistant strains in each patient’s microbiome, than in barrier precautions between patients. Genomic surveillance, where available, helps teams distinguish these scenarios and target their efforts more effectively.

The role of AmpG permease in regulating AmpC enzyme production is one area where basic science may eventually inform new drug targets. Researchers have shown that disrupting the AmpG gene, either by transposon insertion or by loss of its promoter, can restore susceptibility to carbapenems in otherwise resistant strains.²² If a drug could block AmpG function, it might be paired with existing beta-lactam antibiotics to resensitize resistant K. aerogenes strains, conceptually similar to how beta-lactamase inhibitors are paired with penicillins today. That kind of target-specific approach would be a welcome addition to a dwindling antibiotic pipeline.